Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867781 | 0.86 | NPC1 (0.31) | ALOX5APFEN1NPC1 | |
| SCHEMBL6870402 | 0.81 | ALOX5AP (0.32) | ALOX5APFEN1 | |
| SCHEMBL6862708 | 0.81 | KDM5A (0.36) | NPC1 | |
| SCHEMBL6862833 | 0.80 | HTT (0.38) | — | |
| SCHEMBL6867006 | 0.79 | DHFR (0.46) | — | |
| SCHEMBL6041625 | 0.75 | PKM (0.35) | ALOX5APFEN1NPC1 | |
| SCHEMBL23580858 | 0.73 | NPC1 (0.41) | ALOX5APFEN1NPC1 | |
| SCHEMBL30279760 | 0.70 | NPC1 (0.50) | NPC1 | |
| SCHEMBL28917715 | 0.70 | NPC1 (0.50) | NPC1 | |
| SCHEMBL23580911 | 0.70 | HSD17B10 (0.40) | ALOX5APFEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280796-B1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6703397-B2 | REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1280796-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083474-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | IDO1, IDO2, AANAT | ALOX5AP 385/4885FEN1 4430/4885NPC1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.